Molecular Hapten Trap for Biotin Interference Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biotin interference in clinical diagnostic assays leads to instability and false results due to high biotin levels in patient samples, as free biotin competes with solid-phase-bound species for binding sites, compromising assay sensitivity and reliability.
Innovation Solution
A molecular hapten trap is introduced in the reagent formulation, comprising a molecular cage or modified specific binding partner that selectively captures and retains free biotin, preventing it from interfering with the assay, while allowing biotin-conjugated molecules to bind effectively, thus maintaining assay signal integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If free biotin is present in patient samples at high levels, then biotin interference occurs and competes with solid-phase-bound species for binding sites, but assay stability and sensitivity are compromised
Solution Approach 1:
A molecular trap comprising a modified specific binding partner (e.g., streptavidin or avidin) is introduced as an intermediary substance. This trap has altered binding characteristics that allow it to selectively bind free biotin in patient samples, preventing free biotin from competing with solid-phase-bound species for binding sites, thereby eliminating interference while maintaining assay reliability
Solution Approach 2:
The specific binding partner is modified to change its binding parameters - specifically, it has altered affinity or kinetics for binding biotin compared to the solid-phase-bound species. This parameter change enables the trap to preferentially bind free biotin under assay conditions, resolving the contradiction between high biotin presence and assay stability
2Measurement precision
If free biotin competes with solid-phase-bound species for binding sites, then false results occur, but assay sensitivity is reduced
Solution Approach 1:
The molecular trap acts as an intermediary that captures free biotin before it can reach and compete for binding sites on the solid phase. This intermediary approach removes the source of false results while preserving the integrity of the signal generation process, thereby maintaining both accuracy and sensitivity
Solution Approach 2:
The molecular trap is added to the assay mixture to perform preliminary binding of free biotin before the competitive binding step occurs. This preliminary action removes interfering biotin from the system, ensuring that subsequent binding events reflect true analyte concentrations without competition from excess free biotin
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The molecular trap effectively reduces biotin interference, enhancing assay stability and sensitivity by preventing free biotin from competing with biotin-conjugated molecules for binding sites, thereby improving the reliability of diagnostic results.
Implementation Method 1
The article of M. Holzinger et al., Biotin-β-Cyclodextrin: A New Host-Guest System for the Immobilization of Biomolecules, in: Langmuir 28 [2012] 12569 - 12574 discloses an inclusion complex between biotin and β-cyclodextrin.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to methods and compositions to remove or reduce biotin interference from certain assays.